user-avatar
Seeking Alpha

Johnson & Johnson's strong Q3 growth faces a 2027 earnings test

The innovative medicine business posted 7.9% operational growth. TREMFYA generated $2.4 billion in quarterly sales. Those sales offset STELARA's decline.